Related references
Note: Only part of the references are listed.Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
Philip C. Schouten et al.
CLINICAL CANCER RESEARCH (2021)
A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients
Holly LaDuca et al.
GENETICS IN MEDICINE (2020)
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R. E. Miller et al.
ANNALS OF ONCOLOGY (2020)
Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition
Rashid Gabbasov et al.
CANCER BIOLOGY & THERAPY (2019)
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)
Jan Hauke et al.
JOURNAL OF MEDICAL GENETICS (2019)
Ovarian Cancer Statistics, 2018
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands
M. Timmermans et al.
EUROPEAN JOURNAL OF CANCER (2018)
Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer
Michael Dunne et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
W. J. van Driel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer
Jan Hauke et al.
CANCER MEDICINE (2018)
BRCA-like classification in ovarian cancer: Results from the AGO-TRi-trial.
Lisa Katharina Richters et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial
Philip C. Schouten et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms
Philip C. Schouten et al.
MOLECULAR ONCOLOGY (2015)
BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation
Shane R. Stecklein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Rohini Roy et al.
NATURE REVIEWS CANCER (2012)
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Peter Bouwman et al.
NATURE REVIEWS CANCER (2012)
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
M. A. Vollebergh et al.
ANNALS OF ONCOLOGY (2011)
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy
E. H. Lips et al.
ANNALS OF ONCOLOGY (2011)
Joint segmentation, calling, and normalization of multiple CGH profiles
Franck Picard et al.
BIOSTATISTICS (2011)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition
Przemek M. Krawczyk et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH
Simon A. Joosse et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Targeting HSP90 for cancer therapy
D. Mahalingam et al.
BRITISH JOURNAL OF CANCER (2009)
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Joshua Z. Press et al.
BMC CANCER (2008)
Ovarian cancer: a focus on management of recurrent disease
Thomas J. Herzog et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer
RI Olivier et al.
GYNECOLOGIC ONCOLOGY (2006)
Diagnosis of multiple cancer types by shrunken centroids of gene expression
R Tibshirani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
